{"preliminary_commentary":{"by_channel":{"x_thread":16,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04400474\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["cabozantinib","atezolizumab"]],"indication":"advanced and progressive neoplasms of the endocrine system","name":"CABATEN","nct_id":"NCT04400474","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cabaten-nct04400474. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CABATEN","arms":[{"description":"* Cabozantinib 40 mg tablets, oral administration, once daily, continuously.\n* Atezolizumab 1200 mg administered intravenously, every three weeks (cycle).","label":"Cabozantinib 40 mg + Atezolizumab 1200 mg","type":"EXPERIMENTAL"}],"collaborators":["Ipsen","Roche Pharma AG"],"completion_date":{"date":"2023-12-15","type":"ACTUAL"},"conditions":["Neuroendocrine Tumor","Anaplastic Thyroid Cancer","Adenocarcinoma","Pheochromocytoma","Paraganglioma"],"enrollment":{"count":93,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Cabozantinib 40 mg","otherNames":["Atezolizumab 1200 mg"],"type":"DRUG"}],"last_update":"2025-06-19","lead_sponsor":"Grupo Espanol de Tumores Neuroendocrinos","official_title":"Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-11-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"Through study completion, average 1 year"}],"references":[],"start_date":{"date":"2020-10-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study","url":"https://clinicaltrials.gov/study/NCT04400474"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cabaten-nct04400474"}